All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
10 results for "Cancer" and "Prostate and Urologic Cancers" and "Kidney"
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
This study is being done for the following purposes:
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
Protocol No
TRISHULA-TTX-030-002
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
MRTX849 is an investigational drug that is designed to target proteins produced by a specific
gene mutation (KRAS G12C mutation) that is thought to cause cancer cells to grow. MRTX849
is designed to block this mutant protein and thereby prevent the growth and spread of the cancer.
gene mutation (KRAS G12C mutation) that is thought to cause cancer cells to grow. MRTX849
is designed to block this mutant protein and thereby prevent the growth and spread of the cancer.
Protocol No
MIRATI-849-002
Sub Category
A Phase 1/1b, First-In-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Oral TP-1454 Alone And In Combination With Ipilimumab And Nivolumab
The primary purpose of this research study is to determine the preliminary safety of TP-1454 alone, or TP-1454 in combination with ipilimumab and nivolumab, at different doses to find out what effects, if any, it has on people with solid tumors. This study will also gain information about the pharmacokinetics or PK (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body) and pharmacodynamic (PD) biomarkers (which are used to examine the drug effect on the body and/or the tumor).
Protocol No
TOLERO-TP-1454-101
Sub Category
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Protocol No
RPCI-I-191711
Sub Category
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 Naïve and PD-(L)1 Pretreated Patient Populations with Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
Three cohorts (groups) of subjects will be enrolled into the Module A part of the study based on cancer diagnosis, previous treatment and how the cancer responded to the previous treatment that was given. In Cohort 1 patients with gastroesophageal adenocarcinoma will be tested; Cohort 2 will test patients with any type of solid tumor cancer that benefitted previously from an anti-PD-1/PD-(L)1 treatment; and Cohort 3 will test patients that did not benefit from a previous anti-PD-1/PD-(L)1 treatment. The types of solid tumor cancers to be enrolled into Cohort 3 will include: previously treated colorectal cancer, merkel cell carcinoma, and squamous cell skin carcinoma; squamous cancers of the head and neck, cervix, anus,
penis, esophagus, and vulva; hepatocellular carcinoma; biliary tract carcinoma, small-cell lung cancer;
and mesothelioma.
penis, esophagus, and vulva; hepatocellular carcinoma; biliary tract carcinoma, small-cell lung cancer;
and mesothelioma.
Protocol No
BI-1381-0009-MULTI31
Sub Category
Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events
This study is being done to answer the following questions:
Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively?
To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...
Protocol No
ALLIANCE-A151804
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Protocol No
ACCRU-SC-1601
Sub Category
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Protocol No
ECOG-EA8143-PROSPER
Sub Category
PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
This study is being done to answer the following question: Can we prolong life for patients with
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
Protocol No
ALLIANCE-A031704-PDIGREE
Sub Category
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02